Drug-to-market cost falls to under $2bn in five years

Bringing a drug to market is costing companies under $2 billion for the first time in five years, according to a report from IP service provider Clarivate Analytics.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Pharma

Teva faces scrutiny over efforts to curb generic competition

27 August 2026 Turkish regulators are investigating the drugmaker over its efforts to protect its drug from generic rivals—conduct that may sound familiar to European competition watchers.

Pharma

Teva and Aurinia settle generics dispute over lupus drug, voclosporin

21 August 2026 Under the terms of the agreement, which resolves all patent litigation between the biopharma rivals, Teva now has a launch date for its own version of Aurinia's Lupkynis.

Pharma

SK Biopharmaceuticals settles epilepsy generic dispute

20 August 2026 A reported deal with an Indian manufacturer could clear a path for a future generic launch as the Korean drugmaker leverages one of its biggest US products.

More features

10x Genomics wins latest round in Parse patent dispute

Sun Pharma import ban back in force after Squires intervention

White & Case life sciences co-leader moves firms

‘Busiest’ US district patent judge swaps bench for private practice

Exelixis locks down cancer drug exclusivity until 2030 with Fed Circ win

Pinsents expands German patent practice with partner duo

Tempus AI bid to derail DNA patent case hits snag

Top law firms and individuals recognised in WIPR’s UK Patent Rankings 2026

Drug-to-market cost falls to under $2bn in five years

More on this story

Editor's picks

Editor's picks

More features